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ABSTRACT 
Introduction 
Pneumonia is one of the diseases with high child mortality worldwide. Appropriate antibiotic treatment is 
vital for treatment success and minimising emergence of antibiotic resistance. Adherence of prescribers to 
guidelines in the treatment of non-severe Community Acquired Pneumonia (CAP) is one aspect that can 
optimise treatment outcome and help mitigate emergence of antibiotic resistance. This study was 
conducted to investigate antibiotic prescribing patterns of clinical officers and medical assistants in the 
treatment of non-severe paediatric CAP at Limbe Health Centre (LHC). 
Materials and methods 
The study was conducted at LHC. Prescriptions of 53 children aged 2-59 months diagnosed and treated 
for  non-severe CAP  were reviewed for analysis of demographic and treatment data.  
Data collection was conducted from March to May 2017.  Prescribed antibiotics by medical assistants and 
clinical officers were compared using Fischer’s exact test. Correctly and incorrectly prescribed antibiotic 
daily doses in the two groups of prescribers were compared using Chi-square test. In addition, we also 
analysed demographic and academic qualification data for prescribers.  
Results 
The 53 prescriptions included were either for cotrimoxazole (n=29), amoxicillin (n=19) or erythromycin 
(n=5). There was no significant difference in choice of antibiotic for the treatment of non-severe 
paediatric CAP between medical assistants and clinical officers (p=0.2). Based on age or weight of the 
participant, distribution of correctly and incorrectly prescribed daily doses was not significantly different 
in the two groups of prescribers (p>0.5). Of the 53 participants, 30 (57%) were under-dosed. Ten 
participants were under-dosed by 33%, while 20 participants were under-dosed by 34-50% of the 
recommended antibiotic daily dose. Participants were either prescribed a 5-day (n=51) or a 3-day (n=2) 
antibiotic treatment.   
Conclusion  
Amoxicillin, cotrimoxazole and erythromycin were prescribed for the treatment of non-severe paediatric 
CAP at LHC. More than half of the included patients were under-dosed. Antibiotic treatment for 
paediatric CAP at LHC was either for 3 or 5 days. Understanding antibiotic prescribing patterns is 
necessary in designing interventions aimied at improving antibiotic treatment and curbing the emergence 
of antibiotic resistance.  
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CHAPTER 1. INTRODUCTION AND LITERATURE REVIEW 
1.1 Introduction and background 
The World Health Organization (WHO) estimates that 151 million episodes of pneumonia occur in 
developing countries per year, of which 35 million occur in Africa.
1
 In developing countries such as 
Malawi, 20% of child mortality is due to pneumonia.
2 
Viruses are the most common pathogens in 
Community Acquired Pneumonia (CAP) and most bacterial cases are caused by Streptococcus 
pneumoniae and Haemophilus influenzae.
3 
It is estimated that 70% of deaths among children in 
developing countries due to pneumonia are caused by Streptococcus pneumoniae.
4
 Mortality among 
6202 children diagnosed with pneumonia in various hospitals of southern Malawi between July 
2002 and June 2003 was 9.4%.
 5
  
Of late, an increasing proportion of strains of Streptococcus pneumoniae isolated from patients in 
Malawi shows resistance to some antibiotics.
6
 A study conducted at Kamuzu Central Hospital, 
found that 33% of the isolates were resistant to chloramphenicol, 10% were resistant to 
clindamycin, 1.5% to erythromycin, 85.2% to gentamycin, 18.6% to oxacillin, 50.8% to tetracycline 
and 89.4% to cotrimoxazole.
6  
A ten year surveillance study on resistance of invasive Streptococcus pneumoniae to most 
commonly used antibiotics in Malawi, was conducted at Queen Elizabeth Central Hospital (QECH) 
from January 2000 to December 2009.
7 
The study reported that, “Streptococcus pneumoniae had 20-
33% resistance to chloramphenicol, above 90% resistance to cotrimoxazole, 2% to erythromycin, 9-
18% to phenoxymethylpenicillin, 50-63% to tetracycline and 25-37% resistance to 3 or more 
antibiotics”.7 
As a way of achieving best therapeutic outcomes and curbing antimicrobial resistance, it is 
imperative that antimicrobials be prescribed, dispensed and administered correctly. To achieve this, 
design and implementation of treatment guidelines is considered important
46-47
. The Malawi 
Standard Treatment Guidelines (MSTG), British National Formulary (BNF) for children and adults, 
Integrated Management of Childhood Illnesses (IMCI) guidelines and other prescriber’s handbooks 
are being used in Malawi. The MSTG are updated every five years. The Ministry of Health in 
Malawi produces MSTG to standardize prescribing practice across government hospitals in the 
country, but recommends the use of specialised publications in clinical conditions requiring 
specialised attention (page iii).
8 
 
 
2 
 
Limbe Health Centre (LHC) is one of the 25 primary health care facilities managed by Blantyre 
District Health Office (DHO). LHC is one of the 18 health centres which offer both outpatient and 
labour ward services. The remaining seven facilities offer outpatient services only. LHC is located 
close to Limbe market, one of the two major central business districts in the commercial city of 
Blantyre. As such, urban and semi-urban residential areas and suburbs surround LHC.  
In the absence of a secondary level hospital, health centres in Blantyre are overwhelmed with 
patients visiting the health centre for medical attention. With a nation-wide lack of medical doctors, 
clinical officers and medical assistants mostly do diagnosis and prescriptions at LHC. Treatment of 
non-severe paediatric CAP at LHC was based on 2005 IMCI guidelines during the study period.  
The 2005 version of the IMCI guidelines recommends treatment of non-severe CAP with 
cotrimoxazole as first-line antibiotic and amoxicillin as second-line.
9  
 MSTG, however, recommend 
treatment of non-severe pneumonia in children with cotrimoxazole or amoxicillin, and 
erythromycin or doxycycline for non-severe CAP in adults who are allergic to cotrimoxazole or 
amoxicilin.
8
 Hospital guidelines  at QECH recommend amoxicillin 15mg/kg TID for 5 days or 
cotrimoxazole 24mg/kg BID for 5 days in non-severe paediatric  CAP treatment .
10
 
Many countries have published guidelines for treatment of paediatric CAP.
 11-12
 Commonly, not all 
prescriptions are according to the guidelines. “The need to please a patient or the guardian, 
prescriber’s self-confidence, prescriber’s preference drugs, training and specialization, prescriber’s 
beliefs, prescribers’ motivation, work load, inadequate diagnostic equipment, insufficient 
knowledge on antibiotic resistance patterns and lack of knowledge on treatment guidelines” are 
among reasons for non-adherence to treatment guidelines.
13-15 
 1.2 Literature review 
Worldwide, 2500 children under the age of five died of pneumonia per day in 2015,  accounting  for 
16% of all deaths in this age group.
19 
CAP guidelines have emphasized that early initiation of 
antibiotic treatment, correct antibiotic prescribing and administration, correct categorization of 
severity of CAP, and timely analysis of cultures are of paramount importance in management of 
patients.
20 
Studies have shown that adherence to CAP guidelines improves clinical outcomes, 
reduces patient’s mortality, emergence of antimicrobial resistance, length of stay (LOS) in a 
hospital and treatment costs.
 21-23 
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In 2011, the Paediatric Infectious Disease Society of America (PIDS) and Infectious Disease 
Society of America (IDSA) published guidelines for treatment of paediatric CAP recommending 
ampicillin/amoxicillin as first-line antibiotics in the treatment of hospitalized patients.
 24 
After the 
publication of the guidelines, studies have shown that there is a positive relationship between 
adherence to the guidelines and reduced prescription of broad-spectrum antibiotics and increased 
prescription of narrow spectrum antibiotics.
 25-26 
 
Nevertheless, the decrease in prescription of broad spectrum antibiotics did not result in a decrease 
in the LOS and proportion of patients readmitted for paediatric CAP in the United States of 
America (USA).
27
 Similarly, the costs associated with CAP treatment did not decrease significantly 
with the decrease in prescription of broad spectrum antibiotics.
27
 Implementation of local hospital 
CAP guidelines in USA between 2009-11, however, resulted in an increase in the prescription of 
narrow spectrum antibiotics and decreased prescription of broad spectrum antibiotics.
28 
A secondary data analysis conducted in 12 countries in North America, South America, Europe, 
Africa and South-East Asia showed that prescribing according to IDSA/American Thoracic Society 
(ATS) CAP treatment guidelines significantly reduced the in-hospital LOS from a mean of 10 days 
(for those patients whose prescriptions were not guidelines concordant) to a mean of 8 days 
(guidelines concordant).
29 However, this study’s age group was adults ≥ 65 years. 
Recommendation number 31 of the IDSA/ATS guidelines states that, “routine chest radiographs are 
not necessary for the confirmation of suspected CAP in patients well enough to be treated in the 
outpatient setting.”12 Some scholars have disagreed with this  because “half of the ‘high-quality 
evidence’ brought for this assertion (reference 150) is from a single study conducted by Swingler et 
al. in South Africa”.(30) The British Thoracic Society (BTS) guidelines for adult patients do not 
recommend chest radiograph for outpatients.
31 
Nonetheless, the absence of CAP confirmation 
through chest radiograph can lead to antibiotic abuse and overtreatment especially in sub-Saharan 
Africa.
30
 
In Spain, adherence to CAP treatment guidelines reduced mortality and treatment failure.
22
 The 
study was conducted in 13 Spanish hospitals and it recruited 1288 CAP patients. In the study, the 
authors explored factors that influenced adherence to treatment guidelines and also determined 
outcomes of adhering to the guidelines. Physicians had a mean adherence to CAP treatment 
guidelines of 80%. Predictors of adherence to CAP treatment guidelines were the hospital in which 
the physician was practicing, the physician’s confidence, his/her knowledge of both guidelines in 
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use and drugs recommended by the guidelines and number of years she/he has been practicing 
medicine.
22
 There was, however, a decline in adherence to treatment guidelines when prescribing 
for patients in the ICU.
 22
 
Often CAP is associated with comorbidities like asthma, HIV infection and tuberculosis.
33
 These 
comorbidities influence adherence to treatment guidelines, affect choice of antibiotics, increase 
LOS and costs associated with CAP treatment.
33
 A retrospective cohort study from 2007-12 
including 25,124 children admitted with pneumonia in American hospitals, 43% were also 
diagnosed with acute asthma. Those who had asthma co-diagnosis had 5.6% longer LOS and had 
11.8% higher cost of treatment.
33 
Few studies on the treatment of CAP have been conducted in Africa. A retrospective cohort study 
from 2008-10 in Ivory Coast recruited 62 CAP inpatients.
34
 The most prescribed antibiotic was 
amoxicillin + clavulanic acid (42%) followed by netilmicin (35%) and ciprofloxacin (6%). CAP 
prescriptions mostly involved two antibiotics of amoxicillin + clavulanic acid plus netilmicin 
(81%). Only 3.6% of the prescriptions were guidelines concordant.
34
 However, this study did not 
report on whether there was a relationship between adherence to guidelines and outcomes of CAP 
treatment.  
A prospective cohort study in Kenya was conducted to determine the extent and pattern of treatment 
failure in children aged 2-59 months hospitalised for severe and very severe pneumonia.
35
 The 
authors found no difference between guidelines concordant versus non-concordant treatment failure 
in the very severe pneumonia patient group. Despite reporting that non-adherence to guidelines in 
children with severe pneumonia was 41.4% and that it was associated with wheezing on first 
assessment, the study did not report whether treatment failure was associated with lack of adherence 
to treatment guidelines in this group or not.
35
 
There is paucity of data in Malawi on whether prescribers adhere to CAP treatment guidelines or 
not. A study in a rural clinic in Lilongwe assessed the quality of care clinical officers delivered to 
children who presented with pneumonia using WHO’s Integrated Management of Childhood 
Illnesses (IMCI) guidelines.
36
 The study reported that of all the patients assessed, only 1% was 
assessed in all the aspects recommended by the guidelines. Despite having all the characteristics for 
pneumonia diagnosis as stipulated by the guidelines, only 30% (n=76) of 247 of the children were 
diagnosed correctly.
36
 Of the 30%, only 25% (n=19) received correct care. Approximately 41% of 
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the children diagnosed with severe or very severe pneumonia were not admitted.
36
 Reasons for non-
adherence to the guidelines were not investigated.
  
While the study at Lilongwe rural health centre focused on adherence of prescribers to IMCI 
guidelines when examining patients presenting with signs and symptoms of pneumonia, this study 
focussed on how antibiotics are being prescribed in treatment of non-severe paediatric CAP at LHC.  
 
1.3 Problem statement  
There is paucity of  information on how antibiotics are being prescribed in the treatment of non-
severe CAP at LHC.  
1.4 Aims and objectives 
1.4.1 Main objective  
To describe antibiotic drug treatment in the management of non-severe paediatric CAP at LHC. 
1.4.2 Specific objectives  
i. To identify the antibiotics prescribed in the treatment of non-severe paediatric  
CAP at LHC 
ii. To describe antibiotic dosages in treatment of non-severe paediatric  CAP at 
LHC 
iii. To compare duration of antibiotic paediatric  non-severe CAP treatment at 
LHC to that recommended by 2005 IMCI guidelines  
iv. To compare choice of antibiotics, antibiotic dosages and duration of antibiotic 
non-severe CAP treatment prescribed by clinical officers to those prescribed by 
medical assistants 
1.5 Case definition of pneumonia 
1.5.1 Classification of patients with non-severe CAP 
CAP is an acute lung infection that develops in individuals who recently have neither been 
hospitalized nor been exposed to the health care system.
 16-17
 LHC is a primary healthcare facility, 
and only treats outpatients while those who need admission are referred to a secondary or tertiary 
level hospital. Therefore, all pneumonia patients who had their prescriptions written and dispensed 
at LHC pharmacy were regarded as coming from their respective homes (CAP patients). ‘Non-
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severe CAP’ classification was assumed to all paediatric patients who were prescribed oral 
antibiotics only and were not referred to a secondary or tertially level hospital for further treatment.   
1.5.2 Definition of pneumonia  
According to IMCI guidelines and MSTG, pneumonia presents with cough and/or difficult 
breathing, fast breathing and fever. A child aged 2-12 months has fast breathing with ≥50 breaths 
per minute, and a child aged 12-60 months has fast breathing with ≥40 breaths per minute. 8-9  
On examination, a child with cough and/or difficult breathing, fast breathing and fever of ≥37.5° C 
was diagnosed with non-severe pneumonia. Those who, in addition, were found to have chest 
indrawing, stridor in calm child and any other danger signs were diagnosed with either severe or 
very severe pneumonia. Danger signs included vomiting, decreased feeding or drinking, 
convulsions, lethargy and unconsciousness. This study focussed on non-severe CAP.   
The figure 1.1 demonstrates the categorization of severity of CAP. 
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Figure 1.1: An algorithm for categorization of severity of pneumonia. Adopted from The definition of 
pneumonia, the assessment of severity, and clinical standardization in the pneumonia etiology research for 
child health study.
18
 
1.6 Thesis outline  
This thesis has been outlined as follows: 
Chapter 2: Is a manuscript, the purposes of which are: to address the objectives of the study and to 
submit to a peer reviewed journal for possible publication.  
Chapter 3: Conclusions. This chapter shows the extent to which the research question and study 
objectives have been addressed. It also shows the findings of the study in perspective of other 
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research studies. Recommendations, study limitations and significance of the study have been 
outlined in this chapter.  
CHAPTER 2. MANUSCRIPT 
Study results reported in this manuscript are intended for publication in Malawi Medical Journal: 
Matambo E, Småbrekke L, Katundu K, Solomon V. Antibiotic prescribing in treatment of paediatric 
Community Acquire Pneumonia at Limbe Health Centre, Blantyre.  
Contributions:  
Mr E Matambo-principal investigator:  developed the concept, collected and analyzed data and 
drafted the manuscript 
Prof Lars Smabrekke-co-supervisor:  conceptualized the study, designed the study, contributed to 
data analysis and revised the manuscript 
Dr Katundu-co-supervisor: contributed to the writing of the manuscript and data analysis  
Mr Vernon Solomon-principal supervisor: reviewed the  manuscript 
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2.1 Abstract  
Objective: To investigate the antibiotic prescribing patterns of clinical officers and medical 
assistants  in treatment of non-severe paediatric Community Acquired Pneumonia (CAP) at Limbe 
Health Centre (LHC), Blantyre. 
Methods: Data on 53 prescriptions of antibiotics for the treatment of non-severe CAP in children 
aged 2-59 months were collected from March to May 2017 at LHC. Choice of prescribed antibiotics 
by clinical officers and medical assistants was compared using Fischer’s exact test. Difference in 
episodes of correctly and incorrectly prescribed antibiotic daily doses in the two groups of 
prescribers was compared using the Chi-square test.  
Results:  The 53 prescriptions included were either for cotrimoxazole 54.7%  (n=29), amoxicillin 
35.8% (n=19) or erythromycin 9.4% (n=5). There was no significant difference in antibiotic choice 
between clinical officers and medical assistants (p=0.2). Of the 53 participants, 57% were under-
dosed (n=30). Ten participants were under-dosed by 33%, while 20 were under-dosed by 34-50% of 
the recommended antibiotic daily dose. Distribution of correctly and incorrectly prescribed doses 
was not significantly different in the two groups of prescribers based on either weight or age of 
participant (p>0.5). Participants were either prescribed 5-day (n=51) or 3-day (n=2) antibiotic 
treatment.   
Conclusion: Cotrimoxazole, amoxicillin and erythromycin were the prescribed antibiotic treatment 
for paediatric CAP at LHC, and 96% of study participants received treatment for five days. More 
than half of the paediatric patients who received antibiotic non-severe CAP treatment at LHC 
during the study period were under-dosed. Understanding antibiotic prescribing patterns is 
necessary in designing interventions aimed at improving antibiotic treatment and curbing 
emergence of antibiotic resistance. 
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2.2 Introduction 
In Malawi, the childhood mortality in the age group 0-5 years is approxemately 64/1000, of which 
6-40% is caused by Acute Respiratory tract Infections (ARI) including pneumonia.
1
 There are 
variations in the incidence of paediatric ARI in rural and urban areas of Malawi, but the incidence 
in both areas is highest in the winter season.
1-2 
It is estimated that 1000 children died of pneumonia 
in Malawi in 2010 before the introduction of 13-convalent pneumococcal vaccine in November 
2011.
1,3 
Integrated Management for Childhood Illnesses (IMCI) guidelines are the most commonly used 
guidelines for paediatric CAP management in Malawi. Studies have investigated the adherence of 
prescribers to the IMCI guidelines and also clinical outcomes associated with the implementation of 
the guidelines in some parts of Malawi.
4, 5 
A study at Lilongwe health centre reported a poor clinical 
care and low adherence to IMCI guidelines by clinical officers when treating paediatric 
pneumonia.
4
 Despite introduction of IMCI guidelines at Mchinji District Hospital, there was still 
high proportion of children dying of pneumonia and high occurrence of unknown outcomes among 
patients from  2004-6.
5
  At the time of data collection for this study, LHC was using 2005 edition of 
the IMCI guidelines.  
There has not been any study, to our knowledge, investigating prescribing patterns or adherence of 
prescribers to IMCI guidelines in the treatment of paediatric CAP at LHC. This study explored how 
antibiotics are being prescribed in treatment of non-severe CAP in children aged 2-59 months at 
LHC.  
2.3 Methodology 
2.3.1  Study design 
This was a cross sectional records review study. Patients’ prescriptions were reviewed after they 
had been dispensed at the pharmacy during the study period.  
2.3.2 Study site    
a. Setting 
The study was carried out at LHC which is managed by Blantyre District Health Office. As a 
common practice in many health centres in Malawi, medical examinations and patient prescriptions 
were done and written by clinical officers or medical assistants (those with a diploma or certificate 
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in clinical medicine respectively) while drugs at the pharmacy were dispensed by nurses instead of 
pharmacists or pharmacy technicians.  
b. Examining a child for pneumonia at LHC 
When a child with a cough or difficult breathing gets into an examination room, the clinical officer 
or medical assistant also examines the child for possible pneumonia. Often guardians refer to 
difficult breathing as noisy, interrupted or fast.
6 
IMCI guidelines suggest the following steps  when 
examining a child who presents with a cough or difficult breathing:
 6
 
i. Ask the guardian for how long the child has had the cough or difficult breathing 
ii. Ask the guardian to make the child as calm as possible. If the child is asleep, the 
clinician will not ask the guardian to wake him/her up  
iii. Count number of breaths per minute 
A child who is calm, his/her age is between 2-12 months has fast breathing if s/he has ≥ 50 
breaths per minute. A child whose age is between 12 months to 5 years has fast breathing if 
s/he has ≥ 40 breaths per minute. Those who are exactly 12 months have fast breathing if 
they have 40 or more breaths per minute. If the child is asleep, the clinician will count the 
number of breaths while s/he is still asleep.  
iv. Look for chest in-drawing  
The clinical officer or medical assistant will ask the guardian to make the child lie flat 
facing upwards on the guardian’s lap. The child has chest in-drawing if lower ribs (lower 
chest wall) go in when the child breaths in. Chest in-drawing is an indication for pneumonia 
if it is clearly visible and is present at in-breath.   
v. Look and listen for stridor 
Stridor is the harsh noise which can be heard when a child breaths in. The clinician will ask 
the mother to make the child calm again. Then the clinician will look to see when the child 
breathes in and will put his/her ear close to the child’s mouth. If the child’s nose is blocked 
by mucus, the clinician will ask the guardian to clear it so that wheezing sound of the nose 
does not mask the stridor if present. Wheezing sound when a child breaths out is not stridor.  
A child who has a cough and/or difficult breathing plus fast breathing is diagnosed as having 
pneumonia. A child who has a cough and/or difficult breathing, fast breathing, chest in-
drawing, stridor and other danger signs e.g. decreased feeding, vomiting, lethargy; decreased 
consciousness has severe or very severe pneumonia.
6
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2.3.3 Study period 
Data collection for this study was conducted  from March to May 2017.  
2.3.4  Inclusion criteria  
All children aged 2-59 months diagnosed with and treated for non-severe CAP were included in this 
study, including those diagnosed with other comorbidities. 
2.3.5  Excluson criteria 
Those children who were prescribed parenteral antibiotics and those children whose guardians 
declined to give consent.  
2.3.6 Sample size 
According to internal records,  LHC treats >20,000 “under five” children per year. Among these, 
approximately 700 are diagnosed with non-severe CAP. Therefore, the yearly periodic prevalence 
of children diagnosed with non-severe CAP at LHC is between 3.5-4%. Even though data on yearly 
periodic prevalence of children diagnosed with non-severe CAP at LHC is available, there is no 
data on antibiotic prescribing patterns in treatment of non-severe CAP at the health centre. A study 
in rural Lilongwe health centre, Malawi, found that of 247 children who were diagnosed with 
pneumonia, 25% received correct treatment.
4
 
Under the null hypothesis that the proportion of patients receiving correct antibiotic treatment at 
LHC is the same as that of rural Lilongwe health centre, the alternative hypothesis would be that the 
proportion of patients receiving correct antibiotic treatment at LHC is different from that of rural 
Lilongwe health centre. Assuming that the proportion of patients receiving correct antibiotic 
treatment at LHC is 40%, the sample size was calculated using the formula:  
                                  
Where a= One sided percentage point for the normal distribution corresponding to 100%-power 
(0.84 for power of 80%), b= proportion of patients assumed to receive correct treatment at LHC, c= 
null hypothesis proportion i.e. proportion of patients who received correct treatment at rural 
Lilongwe health centre. Therefore a=0.84, b=0.4 and c= 0.25.  
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The calculated sample size was 53 (using 2 decimal places for the entire calculation process). 
Therefore 53 participants were enrolled in the study. 
2.3.7  Data collection tools and methods 
Demographic and treatment information were collected from patient’s health passports using a data 
collection form as shown in appendix 1. Academic qualification and prescriber’s demographic 
characteristics were collected using a data collection form as shown in appendix 2.  
2.3.8 Data collection process 
A medical assistant who was off-duty during the data collection period was recruited and trained as 
a data collection assistant. The individual was trained on how to collect data from health passports 
and prescriptions of patients who met the inclusion criteria using the data collection form. The data 
collection assistant’s desk was stationed close to the exit door of the pharmacy to make it easier for 
guardians of patients to identify him. 
After a prescription of a patient had been dispensed, the guardian together with the patient was 
referred to the data collection assistant. The data collection assistant went through the information 
sheet as shown in appendices 3 or 4 together with the guardian providing more information about 
the study.  
After going through the information sheet, the data collection assistant and the guardian then went 
through the consent form as shown in appendices 5 and 6. Then the data collection assistant asked 
the guardian to give consent by signing or stamping with a thumb print on the consent form before 
beginning to collect data from the patient’s health passport and prescription. Study participants were 
given consecutive numbers beginning from 1.  
All prescriptions should have a signature of the prescriber and the data collection assistant was 
advised to identify each signature by a unique code on the data collection form.  
At LHC pharmacy, there is also a sheet containing names and corresponding signatures for each 
prescriber. By marrying signatures on prescriptions to corresponding names at the pharmacy, the 
data collection assistant was able to identify each prescriber.  
After collection of demographic and treatment data from patients’ prescriptions was completed, the 
data collection assistant went through the consent form on appendix 7 with each prescriber. When a 
prescriber gave consent to participate in the study, s/he was asked to state their highest qualification 
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in medicine. The prescriber’s code and highest qualification in medicine were entered on data 
collection form as shown in appendix 1 while prescriber’s code, highest qualification, gender, age 
and years of practice were entered on data collection form as shown on appendix 2.  
To validate the data collection procedure, the researcher visited the data collection site once a week 
at an unknown time to the data collection assistant.  
2.3.9 Data management  
Once a week, data collection forms were collected, variables coded and entered on an excel sheet.  
Age of patient was calculated by subtracting date of birth from prescription date. Prescribed daily 
dose was calculated as a product of prescribed dose and times of administration per day. 
Recommended daily dose was calculated as a product of recommended dose from BNF or IMCI 
guidelines and times of administration per day.  
 
Excel 2013 computer package was used to create a data base and for storage of coded data. 
Variables were coded as shown in appendix 8.  
2.3.10 Statistical analysis  
Descriptive and analytical measures were used to describe and analyze both patients’ demographic 
variables and treatment variables. Demographic and treatment variables which were analysed 
include: participant’s age, gender and body weight, prescribed antibiotic, dosage, duration of 
treatment, comorbidities, prescriber’s age, gender and qualification. SPSS 24 and Stata 12 were 
used to analyse data. Variables were tested for normality using Skewness-Kurtosis (Jarque Bera) 
normality test. 
Participants’ age and weight and prescribed antibiotic were normally distributed whilst participants’ 
gender, dose, duration of treatment and prescribers’ qualification were skewed. Both parametric and 
non-parametric methods were used to analyse the data.  
Difference in distribution of prescriptions per each antibiotic in the clinical officers and medical 
assistants groups was analyzed using Fisher exact test. The null hypothesis was that there was no 
difference in choice of antibiotics to prescribe in the medical assistants and clinical officers groups. 
The alternative hypothesis was that there was a difference in choice of antibiotics to prescribe in the 
medical assistant and clinical officers groups.  
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Prescribed daily doses were compared to recommended daily doses in IMCI guidelines and BNF for 
children 2011-2012. How prescribed daily doses and recommended daily doses were calculated 
from prescribed doses and recommended doses has been demonstrated in the data management 
section.  IMCI recommended doses for amoxicillin and cotrimoxazole are as shown in the Table 
2.1.  
Table 2.1: Amoxicillin and cotrimoxazole recommended doses 
Age or weight of patient Cotrimoxazole 
BID for 5 days 
Amoxicillin 
TID 5 days 
2-≤12 months (4-<10kg) 240mg 125mg 
12-60 months ( 10-<19kg) 360-480mg 250mg 
 Adopted from Integrated management of childhood illness in Lahej, Yemen: a qualitative analysis from the 
perspective of health providers.
6
   
Prescribed erythromycin daily doses were compared to recommended daily doses in BNF for 
children 2011-2012 because recommended doses for erythromycin are unavailable in IMCI 
guidelines. Recommended doses in BNF for children 2011-2012 are as shown in Table 2.2. 
Table 2.2: Erythromycin doses in treatment of non-severe paediatric CAP 
Age Erythromycin 
QID for 5 days 
 
1≤ 24 months 125mg 
24-96 months 250mg 
 Adopted from BNF for children 2010–2011.7  
Antibiotics for non-severe paediatric CAP can be prescribed based on age or weight of the patient, 
especially in children. As such, when comparing prescribed daily doses to recommended daily 
doses, both the age and the weight of the participant were considered. A prescribed daily dose 
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would, therefore, be correct if it matches with either recommended weight dependent daily dose or 
recommended age dependent daily dose or both.   
Recommended erythromycin weight dependent doses for non-severe paediatric CAP are not 
available in BNF for children 2011-2012. As such prescribed erythromycin daily doses were 
compared to recommended erythromycin age dependent daily doses only.   
Correctly and incorrectly prescribed daily doses per antibiotic in the two groups of prescribers were 
compared using Chi-square test. Since clinical officers did not prescribe erythromycin, only 
correctly and incorrectly prescribed daily amoxicillin and cotrimoxazole doses were compared in 
the two groups of prescribers in statistical analyses. 
The null hypothesis for comparing the correctly and incorrectly prescribed daily doses was, “no 
difference between amoxicillin and cotrimoxazole daily doses in the two groups of prescribers”. 
The alternative hypothesis was that correctly and incorrectly prescribed daily doses of amoxicillin 
and cotrimoxazole were different between medical assistants and clinical officers.  
Correctly and incorrectly prescribed daily doses of amoxicillin and cotrimoxazole were also 
compared using Chi-square test. The null hypothesis was that there was no difference in distribution 
of correctly and incorrectly prescribed daily doses of amoxicillin and cotrimoxazole while the 
alternative was that there was a difference in distribution of correctly and incorrectly prescribed 
amoxicillin and cotrimoxazole daily doses.  
Duration of antibiotic treatment was recorded as each prescription was being reviewed.  
2.3.11 Ethical consideration 
The research proposal was submitted to Malawi College of Medicine Research Ethics Committee 
(COMREC) for approval before being submitted to UKZN Biomedical Research Ethics Committee 
(BREC) for a second approval. 
The study involved acquiring demographic and treatment information through reviewing of 
patients’ health passports and prescriptions. Consent was sought from guardians of patients before 
health passports and prescriptions were reviewed. Consent form (appendix 5) was administered to 
the guardians. The consent form was also translated into Chichewa (appendix 6), for those who 
preferred vernacular language. Guardians gave consent by signing at the end of the consent form.  
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Those who were not able to read or write but were able to understand either of the 2 languages 
(English or Chichewa) had the consent form of which language they were able to understand read 
out to them. They gave consent by stamping at the end of that consent form with their thumb.  
The study also involved  acquiring demographic and academic qualifications data from prescribers. 
Consent from prescribers was sought using consent form in appendix 7. The consent forms and all 
data collection forms were safely locked up. The CAP database which was created was stored on a 
computer protected by a password. 
2.4 Study findings 
2.4.1  Study participants 
In this study, 95 children aged 2-59 months were eligible for inclusion. Of the possible participants, 
28 were excluded because they were prescribed parenteral in addition to oral antibiotic(s). 
Guardians of 14 children declined to give consent. Figure 2.1 shows the recruitment into the study.  
 
Figure 2.1:Flow diagram of inclusion 
 
Participants’ base-line data was analysed based on gender and subgroups of age, weight and 
presence of other comorbidities. The age of most of the study participants was below 24 months 
(n=33). Table 2.3 illustrates base-line data for study participants.  
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Table 2.3: Base-line data for study participants  
 Gender 
Total 
 Girls (n=25) Boys (n=28) 53 
Mean age (SD) 
≤12 months 
13-24 months 
25-36 months 
37-48 months 
49-59 months 
22.2 months (15.8) 
7 
9 
5 
2 
2 
19.8 months (14.1) 
13 
4 
6 
5 
0 
 
20 
13 
11 
7 
2 
Other comorbidities 
Asthma (n=3) 
Diarrhea (n=4) 
Other (n=8) 
 
1 
1 
5 
 
2 
3 
3 
 
3 
4 
8 
Mean weight (SD) 10.9 kg ( 9.7) 10.1 kg ( 9.1)  
 
Six prescribers prescribed antibiotics to the non-severe paediatric CAP study participants during the 
study period: 4 medical assistants and 2 clinical officers. Table 2.4 gives more information on 
prescriber characteristics.  
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Table 2.4 : Prescriber's characteristics 
 
Female Male 
 Medical assistant  
(n=1) 
Clinical officer 
(n=1) 
Medical assistant 
(n=3) 
Clinical  officer 
(n=1) 
Age in years  
(SD) 
 
36 29 40 (15.5) 31 
Years of 
practice 
8 5 1=21 
1=7 
1=6 
4  
 
2.4.2  Treatment information 
a. Prescribed antibiotics 
Medical assistants wrote 66% of the prescriptions and clinical officers wrote 34%. Amoxicillin, 
cotrimoxazole and erythromycin were prescribed for treatment of non-severe paediatric CAP. Of 
the 53 antibiotic prescriptions, 54.7% (n=29) were for cotrimoxazole, 35.8% (n=19) for amoxicillin 
while erythromycin was the least prescribed antibiotic with 9.4% (n=5). Table 2.5 denotes 
prescribing by medical assistants and clinical officers.  
Table 2.5: Antibiotic prescribing by clinical officers and medical assistants 
 Prescriber's qualification  
Prescribed antibiotics Clinical officers Medical assistants 
Amoxicillin 6 13 
Cotrimoxazole 12 17 
Erythromycin 0 5 
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Clinical officers did not prescribe erythromycin for the treatment of non-severe paediatric CAP. 
There was no statistically significant difference in choice of antibiotics between clinical officers and 
medical assistants (p>0.2). 
b. Prescribed daily doses 
Daily doses of the three prescribed antibiotics (amoxicillin, cotrimoxazole and erythromycin) as 
recommended in IMCI guidelines and BNF were used to categorize prescribed daily doses as either 
correct or incorrect as shown in tables 2.6 and 2.7. 
Table 2.6: Correctly and incorrectly prescribed weight dependent doses  
  Prescriber's qualification  
  Clinical officer  Medical assistant 
Prescribed 
antibiotic  
Correctly 
prescribed daily 
doses  
Incorrectly 
prescribed daily 
doses  
Correctly 
prescribed daily 
doses  
Incorrectly 
prescribed daily 
doses  
Amoxicillin  5 1 8 5 
Cotrimoxazole 4 8 4 13 
 
Table 2.7 : Correctly and incorrectly prescribed age dependent doses  
 Prescriber’s qualification 
 Clinical officer Medical assistant 
Prescribed 
antibiotic 
Correctly 
prescribed daily 
dose 
Incorrect 
prescribed daily 
dose 
Correct 
prescribed daily 
dose 
Incorrect 
prescribed 
daily dose 
Amoxicillin 4 2 5 8 
Cotrimoxazole 2 10 3 14 
Erythromycin 0 0 2 3 
 
         
Amoxicillin was more frequently correctly prescribed in the weight dependent daily doses (13 of 19 
prescriptions) and erythromycin in the age dependent daily doses (2 of 5 prescriptions) then 
cotrimoxazole in the weight dependent daily doses (8 of 29 prescriptions). Considering either age or 
weight of the participant, amoxicillin was more correctly prescribed than cotrimoxazole (p<0.01).  
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Of the incorrectly prescribed antibiotic daily doses, none was an overdose. Considering either age 
or weight of the participant, 30 participants were under-dosed: 10 by 33% of the recommended 
daily dose and 20 by 34-50% of the recommended daily dose. Cotrimoxazole was the most poorly 
prescribed antibiotic accounting for 21 under-doses of the 29 cotrimoxazole prescriptions, then 
erythromycin (2 under-doses of 5 prescriptions) and amoxicillin (6 under-doses of 19 prescriptions). 
Table 2.8 below demonstrates the under-dose per prescriber’s qualification. 
Table 2.8 : Under-dose considering either age or weight of the participant 
 Prescriber's qualification 
 
Clinical officers  Medical assistants 
Under-dose  
Under-dose by 
33% of 
recommended 
daily dose 
Under-dose by 34-
50% of the 
recommended 
daily dose 
Under-dose by 
33% of 
recommended 
daily dose 
Under-dose by 
34-50% of the 
recommended 
daily dose  
Prescribed 
antibiotics 
        
Amoxicillin 0 1 0 5 
Cotrimoxazole 8 0 2 11 
Erythromycin  0 0 0 3 
 
Based on both weight and age of the participant, there was no significant difference in distribution 
of correctly and incorrectly prescribed doses of amoxicillin and cotrimoxazole between medical 
assistants and clinical officers (p> 0.5). 
c. Duration of antibiotic treatment 
Of all cases in the study, 96% (n=51) were prescribed a 5-day oral antibiotic treatment course.  
Medical assistants wrote two prescriptions of 3-day antibiotic treatment courses: one treatment with 
cotrimoxazole and the other with amoxicillin. 
2.5 Discussion 
2.5.1 Choice of antibiotic 
Cotrimoxazole was the frequently prescribed antibiotic during the study period by both clinical 
officers and medical assistants. This was expected because LHC was using the 2005 IMCI 
guidelines at the time of the study, which recommend cotrimoxazole as first-line treatment for non-
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severe pneumonia.
6 
 The current 2014 IMCI guidelines recommend amoxicillin as the first-line and 
cotrimoxazole as the alternative.
8
  
WHO released the current guidelines in 2014 and data collection for this study was conducted from 
March to May 2017. It is not known why LHC was still using outdated guidelines three years after 
updated guidelines were released. The recommendation of cotrimoxazole as first-line antibiotic for 
paediatric CAP treatment in the 2005 IMCI guidelines is not supported with references indicating 
superior outcome of cotrimoxazole. 
There may be several reasons leading to that recommendation: for some countries, cotrimoxazole is 
cheaper and patients are more compliant to cotrimoxazole treatment than amoxicillin.
9
 In Malawi,  
the average price of amoxicillin 250mg capsule is $ 0.057 while cotrimoxazole 480mg tablet is $ 
0.045.
10
 An adult non-severe CAP treatment of 5-day amoxicillin 500mg TID costs $ 1.71 while a 
cotrimoxazole 5-day treatment of 960mg BID costs $ 0.9.  
There are no published data on prices of paediatric formulations but random market surveillance 
shows that the average price of a 100mL amoxicillin, 125mg/5mL bottle costs $ 1.16 and a 100mL 
cotrimoxazole, 120mg/5mL bottle is also being sold at the same average price. Therefore, adult 
CAP cotrimoxazole treatment is cheaper than amoxicillin adult CAP treatment while the cost of 
paediatric CAP amoxicillin treatment may be the same as paediatric CAP cotrimoxazole treatment 
depending on age or weight of participant. 
Compliance of patients (2-59 months) to amoxicillin pneumonia treatment has not been studied in 
Malawi, but one study showed 9.5% non-adherence to cotrimoxazole in pneumonia treatment.
11
 The 
non-adherence was associated with an increase in treatment failure rate (19% versus 14% in the 
treatment compliant group).
11
 
Studies have identified differences in effectiveness of cotrimoxazole versus amoxicillin in treatment 
of non-severe pneumonia. Some indicate that there is no significant difference in effectiveness of 
cotrimoxazole and amoxicillin whilst others have shown that amoxicillin is more effective than 
cotrimoxazole.
9, 12
 Studies have also differed on failure rates of cotrimoxazole and amoxicillin 
pneumonia treatments. While some have reported that the failure rates are the same, studies in India 
and Vietnam have shown cotrimoxazole treatment to have a higher failure rate.
9, 13
 In Malawi, CAP 
treatment failure rate is also high due to resistant Streptococcus pneumoniae and Haemophilus 
influenzae strains.
 14-17 
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In the early 2000, before the rolling out of the cotrimoxazole prophylaxis against HIV opportunistic 
infections in Malawi, Streptococcus pneumoniae resistance to cotrimoxazole was still significantly 
high (41-44% of isolates) due to sulfadoxine-pyrimethamine use in treatment of malaria.
19 
After 
rolling out of the cotrimoxazole prophylaxis against HIV related opportunistic infections, 
Streptococcus pneumoniae resistance to cotrimoxazole has significantly increased to 90-96% of 
Streptococcus pneumoniae isolates.
14,16-17
Resistance of Streptococcus pneumoniae to amoxicillin on 
the other hand seems lower than that of cotrimoxazole (9-18% of isolates).
16-17, 20
 Therefore the 
recommendation of the current IMCI guidelines to treat non-severe pneumonia with amoxicillin as 
first-line instead of cotrimoxazole tallies with local antibiotic resistance patterns. 
However, increase in antibiotic resistance is a common trend to almost all antibiotics used in 
Malawi. This raises concerns of effectiveness of antibiotic treatments in the near future.
15
 
Alternative treatments will soon be required due to the ineffectiveness of the current antibiotics to 
treat bacterial pneumonia.
15, 45
 
Medical assistants prescribed erythromycin to five study participants. There is evidence that 
macrolides are as effective as amoxicillin in treatment of pneumonia, and newer macrolides seem to 
be effective in treatment of non-severe pneumonia caused by multidrug resistant Streptococcus 
pneumoniae.
21-22 
However, the IMCI guidelines do not recommend erythromycin as pneumonia 
treatment and MSTG recommend pneumonia treatment with erythromycin only in adults.
23
 
Even though erythromycin is not one of the drugs recommended for treatment of non-severe 
paediatric pneumonia in IMCI guidelines and MSTG, an erythromycin prescription was not 
considered as a prescribing error. According to a WHO report on pneumonia treatment, macrolides 
can be used for treatment of pneumonia as second-line.
24 
For the five participants who were 
prescribed erythromycin in this study, it is unclear if the prescribers had the intention of prescribing 
a second-line antibiotic  therapy. 
Eligibility of a participant to second-line therapy was not investigated under this study nor did the 
study investigate treatment failure associated with amoxicillin or cotrimoxazole treatment. One 
Canadian study reported that 74% of prescribers chose a macrolide for treatment of paediatric 
pneumonia which presented with no comorbidities.
25 
It is possible that medical assistants 
infrequently prescribe erythromycin for treatment of non-severe paediatric CAP as first-line 
antibiotic.  
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MSTG recommend prescribing erythromycin to pneumonia in adult patients who are allergic to 
penicillin and cotrimoxazole. MSTG do not give the alternative of administering erythromycin for 
treatment of non-severe paediatric pneumonia. We did not investigate the presence of allergies to 
penicillin or cotrimoxazole in the study participants, and so it is unclear whether the five study 
participants who were prescribed erythromycin were allergic to penicillin and cotrimoxazole. 
It should be noted that penicillin allergies are very rare, occurring in 1-5 cases per 10 000 penicillin 
therapies globally.
26
 There is no documented evidence of prevalence of penicillin allergies in 
Malawi but it is highly unlikely that it is higher than the global estimate.  
Since the erythromycin was prescribed by experienced medical assistants, it may be suspected that 
prescriber’s qualification and years of practice had an influence on choice of antibiotic to prescribe 
in this study. Some literature has shown that prescriber’s qualification and years of practice 
influence choice of an antibiotic to prescribe.
27
 
2.5.2 Antibiotic doses 
Of the 53 study participants, 10 were under dosed by 33% whilst 20 were under dosed 34-50% of 
the recommended daily dose. BNF for children 2011-12 indicates that the erythromycin dose for 
pneumonia treatment and other acute respiratory tract infections should be double the standard 
dose.
7 
WHO revised classification and treatment of childhood pneumonia guidelines state that 
higher dose (80-90mg/kg/day) amoxicillin is more effective in treatment of both Streptococcus 
pneumoniae and Haemophilus influenzae than standard dose (45mg/kg/day). 
24
 
In this study, all doses which were classified as ‘under-dose’ were actually standard doses. The 
objectives of this study were not to identify reasons for prescribing standard doses. It is therefore 
unknown whether the prescribers at LHC are aware that the recommended doses for amoxicillin, 
cotrimoxazole and erythromycin are double the standard dose in paediatric pneumonia treatment. A 
follow up study can be conducted at LHC to investigate treatment outcomes of treating non-severe 
paediatric pneumonia with either standard amoxicillin, cotrimoxazole or erythromycin doses. An 
interventional study can also be conducted at LHC to investigate effectiveness of double dose 
versus stardard dose amoxicillin, cotrimoxazole or erythromycin in treatment of non-severe 
paediatric CAP.  
A higher amoxicillin dose maintains drug serum levels above the Minimum Inhibitory 
Concentration (MIC) for more than 40% of the dosing interval.
24
 Maintaining serum level above 
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MIC for more than 40% of the dosing interval has been found to be effective against penicillin 
resistant Streptococcus pneumoniae and Haemophilus influenzae in otitis media.
 24, 28
 
It is interesting to note, however, that none of the publications which have been referenced in the 
revised WHO classification and treatment of childhood pneumonia guidelines in support of higher 
dose amoxicillin was about pneumonia treatment. In addition, the referenced studies were 
conducted between the years of 1985 and 1998. 
28-34
 A more recent clinical trial showed that there is 
no statistically significant difference in effectiveness between standard dose and high dose 
amoxicillin in treatment of otitis media.
35
 Another recent study has reported that high dose 
amoxicillin with clavulanate was superior to standard dose amoxicillin in treatment of otitis media 
only in children of less than 20kg.
36
 
As of March 2016, there was no research study or clinical trials in USA or Canada to act as 
evidence that high dose amoxicillin is superior to standard dose amoxicillin in treatment of 
paediatric pneumonia. Still, high dose amoxicillin therapy is used in Canada and USA for treatment 
of paediatric pneumonia as a result of expert opinion.
37
  
A study in Pakistan comparing treatment of pneumonia with standard dose cotrimoxazole to high 
dose cotrimoxazole found that the difference in effectiveness of the two doses was statistically 
insignificant.
38
 
Therefore, there  is insufficient evidence from literature to predict that patients who were under-
dosed at LHC had increased risk of poor treatment outcomes or that the prescribing patterns 
influenced emergence of antibiotic resistance. It could, however, be said that the prescriptions were 
not guidelines concordant in terms of antibiotic doses for amoxicillin, cotrimoxazole and 
erythromycin in treatment of non-severe paediatric pneumonia. And more importantly, the 
prescribed doses were not concordant to the most recent IMCI guidelines.  
A study should be conducted at LHC to investigate outcomes associated with treatment of 
paediatric CAP with standard doses. Possibly, a clinical trial should also be conducted to investigate 
effectiveness of double dose versus standard dose amoxicillin or cotrimoxazole in treatment 
paediatric CAP in Malawi. Since LHC uses IMCI guildienes, it would be proper to design 
interventions aimed at encouraging prescribers to prescribe double dose amoxicillin or 
cotrimoxazole as recommended by the guidelines.  
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Tables 2.1 and 2.2 give age and weight ranges and their corresponding ideal doses. The 
recommended ideal dose regimen and age ranges were given to make drug administration easier and 
also considering the dosage forms which are readily available.
6
 These tables have been adopted 
from the IMCI guidelines (2005 edition) and BNF for children 2011-2012. From that recommended 
dose regimen, it was possible to precisely calculate the extent of the under-dose and the percentage 
of the under-dose.  
2.5.3 Duration of antibiotic treatment 
Of the 53 antibiotic treatments, 2 treatments were for 3 days, and the rest were for 5 days. The 3 day 
antibiotic treatments were prescribed by medical assistants. IMCI guidelines recommend 5 days 
duration for treatment with amoxicillin or cotrimoxazole.
6
 
There is however some literature which suggests that 3 day amoxicillin treatment is equally 
effective as the 5 day treatment.
39-40
 In both clinical trials, cure rates and failure rates were not 
significantly different. There was also no difference in effectiveness of 3 day amoxicillin versus 5 
day cotrimoxazole in treatment of non-severe pneumonia in another clinical trial.
41
 A clinical trial in 
Indonesia and Bangladesh also reported that there was no statistically significant difference in cure 
rates and failure rates of 3 day cotrimoxazole and 5 day cotrimoxazole in treatment of pneumonia.
42
 
The reasons why the two study participants were prescribed 3 day treatments were not investigated. 
However, from the literature, there would probably not be significant effects on the cure rate or 
treatment failure following the 3 day treatments. It may also be investigated as to why it was only 
medical assistants who prescribed 3 day treatments and not clinical officers. 
All the five erythromycin prescriptions were for five days. There are no published studies 
comparing effectiveness of 3 day erythromycin to 5 day erythromycin in treatment of non-severe 
pneumonia. One study found no statistical difference in cure rates and treatment failure when total 
azithromycin dose was spread across 3 days duration and 5 days duration.
43
  
2.5.4 Prescribing according to IMCI guidelines 
From the study results, it can be said that clinical officers’ choice of antibiotics and duration of 
treatment were more guidelines concordant than medical assistants’. Since clinical officers have a 
higher qualification than medical assistants, it may be speculated that the academic qualification 
had an effect on adherence to treatment guidelines by the clinical officers (keeping all other factors 
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constant).
27
 On the other hand, it may be observed from the study results that medical assistants had 
more years of practice as compared to clinical officers. 
Considering academic qualification and years of practice on adherence to treatment guidelines, 
senior prescribers seem to rely more on experience and personal knowledge than treatment 
guidelines.
27
 Since clinical officers at LHC have a higher qualification but less number of years of 
practice than medical assistants, it can still be debated as to whether their academic qualification 
and fewer number of years of practice had an effect on their adherence to treatment guidelines. 
It is also possible that the clinical officers were trained in the implementation of the IMCI 
guidelines on pneumonia treatment whilst the medical assistants were not. It may also be possible 
that the medical assistants were not aware of the treatment guidelines used for pneumonia treatment 
at LHC during  the study period. 
Erythromycin was prescribed by medical assistants only. Prescribers adjust their antibiotic 
prescribing behaviour according to the clinical groups they identify themselves with.
27
 It is therefore 
not surprising to note that erythromycin was prescribed in the medical assistants group only because 
a medical assistant would identify themselves with a group of fellow medical assistants. 
Lack of adherence to treatment guidelines can also be attributed to lack of pharmacy personnel at 
LHC. Nurses dispense medicines at LHC due to shortage of pharmacy personnel in Malawi. In 
other countries pharmacy personnel have been shown to improve adherence to treatment guidelines 
by ensuring that best drugs available are prescribed and administered  to patients correctly . 
44-45
  
It should also be noted that the data collection forms used to collect data from non-severe paediatric 
CAP patients and the prescribers were not validated. As such, some important elements or variables 
may have not been indicated on the forms and consequently such data was not collected. May be the 
data would have been different if the data collection forms were validated. 
2.5.5 Choice of antibiotic therapy in context of antibiotic resistance patterns 
In this study, cotrimoxazole was the most prescribed antibiotic (29 of 53 prescriptions). In the wake 
of increased cotrimoxazole resistant Streptococcus pneumoniae and Haemophilus influenzae, it 
makes more sense to switch to amoxicillin as first-line treatment in non-severe pneumonia 
treatment.
14-17
 Evidence shows that Streptococcus pneumoniae and Haemophilus influenzae 
resistance to amoxicillin is lower than cotrimoxazole in the local setting.
14-17, 20
  
2.6 Study limitations 
 
 
29 
 
The study was not designed to investigate whether categorization of severity of pneumonia 
diagnosis was correctly done. As such ‘non-severe paediatric pneumonia’ diagnosis was perceived 
to all paediatric patients who were diagnosed with pneumonia, treated as outpatients and were 
prescribed oral antibiotic(s) with no parenteral antibiotic(s).  
 2.7 Recommendations 
Further studies on adherence of prescribers to IMCI guidelines at LHC and other primary health 
centres in Malawi need to be conducted on non-severe pneumonia treatment. Reasons for non-
adherence should be investigated (if they do not adhere to guidelines when prescribing) or what 
lessons can be learnt from their prescribing behavior (if they adhere to guidelines). Treatment 
outcomes in the IMCI guidelines adherent and non-adherent groups should also be investigated. 
There are also no clear guidelines of prescribing second-line therapy in treatment of non-severe 
paediatric CAP at LHC and other health centres in Malawi. There are no studies on effectiveness of 
second-line drugs like erythromycin in treatment of non-severe paediatric CAP in Malawi.  
2.8 Conclusion  
Cotrimoxazole, amoxicillin and erythromycin were prescribed for treatment of non-severe 
paediatric CAP at LHC during the study period. There was no difference in prescription of correct 
and incorrect daily doses of amoxicillin and cotrimoxazole between medical assistants and clinical 
officers. Clinical officers were more adherent to IMCI guidelines in terms of antibiotic choice and 
duration of antibiotic therapy than medical assistants. Antibiotic non-severe paediatric CAP 
treatment was for 3 days or 5 days. Understanding antibiotic prescribing patterns is necessary in 
designing interventions aimed at improving treatment and curbing emergence of antibiotic 
resistance. 
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CHAPTER 3. CONCLUSIONS 
The current study investigated antibiotic prescribing patterns in treatment of non-severe CAP in 
children aged 2-59 months at LHC. Amoxicillin, cotrimoxazole and erythromycin were prescribed 
for treatment of  non-severe paediatric CAP during the study period. Amoxicillin and cotrimoxazole 
were prescribed by both clinical officers and medical assistants while erythromycin was prescribed 
by medical assistants only. Cotrimoxazole was the mostly prescribed antibiotic since it was the 
recommended first-line antibiotic for non-severe paediatric CAP treatment in 2005 IMCI guidelines 
which LHC was using at the time of study.
9
  
Studies at rural Lilongwe health centre and Mchinji District hospital investigating adherence of 
prescribers to IMCI guidelines when treating paediatric pneumonia  reported  poor adherence of 
precribers to the guidelines.
36, 45
 In this study, more than half of the study participants were under-
dosed. Both clinical officers and medical assistants prescribed standard amoxicillin and 
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cotrimoxazole doses instead of double doses for paediatric CAP treatment, however, amoxicillin 
doses were more correctly prescribed than cotrimoxazole doses. There is no clear basis for 
recommending amoxicillin and cotrimoxazole double doses to standard doses in paediatric CAP 
treatment since studies comparing effectiveness of double doses to standard doses have yielded 
conflicting results.
40-43
  
2014 IMCI guidelines recommend amoxicillin as first-line and cotrimoxazole as the alternative.
44
 
Using amoxicillin as first-line CAP treatment in the local setting can be supported by lower 
prevalence of amoxicillin Streptococcus pneumoniae and Haemophilus influenzae resistance
6,37-38
 
and that amoxicillin was more correctly prescribed than cotrimoxazole in this study.  
The duration of antibiotic treatment was either 3 days or 5 days. The shorter 3-day antibiotic 
treatments were prescribed by medical assistants only. Based on 2005 IMCI guidelines, clinical 
officers chose antibiotics and prescribed duration of antibiotic therapy more correctly than medical 
assistants.  
Even though paediatric CAP mortality rate is decreasing globally, it still accounts for 4-6% of child 
mortality in Malawi.
39
 Unfortunately, Streptococcus pneumoniae and Heamophilus influenzae 
resistance to commonly used antibiotics in Malawi is high.
6-7,37-38
 Understanding prescribers’ 
antibiotic prescribing patterns is necessary in designing interventions aimed at improving antibiotic 
prescribing behaviour, patient management and mitigating emergence of antibiotic resistance. 
The present study was not designed to investigate whether categorization of severity of pneumonia 
diagnosis was correctly done. As such ‘non-severe paediatric pneumonia’ diagnosis was perceived 
to all paediatric patients who were diagnosed with pneumonia, treated as outpatients and were 
prescribed oral antibiotic(s) with no parenteral antibiotic(s). A study should be conducted to 
investigate adherence of prescribers to IMCI guidelines when examining a child for pneumonia.  
Ideally a pilot study should have been conducted to establish antibiotic prescribing patterns in 
treatment of non-severe CAP at LHC before this study. However, time and resource constraints 
made it impossible to conduct a pilot study. This study, therefore, can only be used as a pilot study 
for other major studies in CAP treatment which can be conducted at LHC.  
Further studies on adherence of prescribers to IMCI guidelines at LHC and other primary health 
centres in Malawi need to be conducted on non-severe pneumonia treatment. Reasons for non-
adherence should be investigated (if they do not adhere to guidelines when prescribing) or what 
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lessons can be learnt from their prescribing behavior (if they adhere to guidelines). Treatment 
outcomes in the IMCI guidelines adherent and non-adherent groups should also be investigated.   
There are also no clear guidelines for prescribing second-line therapy in treatment of non-severe 
paediatric CAP at LHC and other health centres in Malawi. There are no studies on effectiveness of 
second-line drugs like erythromycin in treatment of non-severe paediatric CAP in Malawi.  
As reported in this study, more than half of the study participants were prescribed standard 
amoxicillin, cotrimoxazole and erythromycin doses despite the double antibiotic dose 
recommendation. No study, to our knowledge, has been conducted in Malawi to compare 
effectiveness of double dose to standard dose of these antibiotics in treatment of non-severe 
paediatric CAP. Another study can compare effectiveness of 3-day versus 5-day non-severe 
paediatric CAP antibiotic treatment in Malawi.  
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APPENDICES 
1. Data collection form for non-severe CAP participants 
A. Patient demographic data 
Case # Date of birth Prescription date 
(day/month/year) 
Patient’s weight 
(kg) 
Patient’s sex  
     
 
B.  Non-severe CAP treatment  
Prescribed antibiotic (s) 
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Drug name: 
Strength: 
Route of administration: 
Times of administration per day: 
Duration of treatment:  
C. Presence of other comorbidities 
          Other comorbidities Yes No 
HIV/AIDS   
Tuberculosis   
Asthma   
Other (Specify)   
 
D. Prescriber’s information 
Prescriber’s code Prescriber’s highest academic qualification in 
medicine 
  
  
2. Data collection form for prescribers 
Prescriber’s code  
Age  
Years of practice  
Gender  
Qualification  
 
3. Information sheet 
I am Ernest Matambo, a University of Malawi (UNIMA) and University of Kwa-Zulu Natal 
(UKZN) masters student. As a partial fulfilment to my masters degree, I am conducting a research 
study aimed at exploring treatment which non-severe paediatric community acquired pneumonia 
patients receive. I have keen interest in understanding how health practitioners choose which drugs 
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to prescribe, in what strength and also duration of their usage. I hope this study will provide 
information to the Malawian health authorities which is vital in maintaining and improving 
standards of care. 
In order to do this research, I will need to have access to prescription information as well as basic 
demographic information of research participants. The information includes date of birth, gender, 
body weight, prescribed drug, route of administration, duration of treatment and other diseases 
which the participant may have been diagnosed with. And so I would like to invite the participation 
of your son/daughter/ dependant into the study. I would need to have your consent to have access to 
his/her demographic and treatment information. This will take approximately 10 minutes of your 
time.  
The information acquired will be kept strictly confidential; only accessible to the researcher and his 
supervisors. All information acquired will be coded. It will be presented in numbers and figures in 
all out puts e.g. dissertation, conference papers and publications.  
The study has been approved by Biomedical Research and Ethics committee (BREC) of UKZN and 
College of Medicine Research and Ethics Committee (COMREC) of UNIMA. Participation is 
voluntary: you can turn down the invitation to participate or withdraw your son/daughter/dependant 
from the study at any point without fear or subjection to any reprisals. Participation is entirely for 
free and that there are no any incentives to participate. Your consent will be appreciated as it will 
contribute to knowledge in the field of paediatric community acquired pneumonia treatment.      
If you have any questions or concerns related to the study, do not hesitate to contact the researcher 
on his mobile phone number +265 (0)993 089 868 or on his email address 
ebmatambo75@gmail.com. You may also direct your concerns to his supervisors on 
vernonsolomon@gmail.com, lars.smabrekke@uit.no and kkatundu@medcol.mw. Complaints can 
also be addressed to the chairperson of BREC and COMREC as shown in the addresses below.  
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION  
Research Office, Westville Campus  
Govan Mbeki Building  
University of KwaZulu-Natal 
Private Bag X 54001, Durban, 4000  
KwaZulu-Natal, SOUTH AFRICA  
Tel: 27 31 2602486 - Fax: 27 31 2604609  
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Email: BREC@ukzn.ac.za   
 
COLLEGE OF MEDICINE RESEARCH AND ETHICS COMMITTEE 
College of Medicine 
Private bag 360 
Chichiri, Blantyre 3 
Email: comrec@medcol.mw 
 
4. Uthenga wakafukufuku 
Ndine Ernest Matambo, ophunzira wakusukulu za ukachenjede za University of Malawi (UNIMA) 
ndi University of Kwa-Zulu Natal (UKZN). Ngati mbali imodzi yokwaniritsa maphunziro anga a 
masters degree, ndikupanga kafukufuku amene cholinga chake ndikuunikira chithandizo chimene 
ana odwala chibayo amalandira pa chipatala chaching’ono cha Limbe. Ndili ndi chikhumbokhumbo 
chofuna kumvetsetsa kuti madotolo amasankha motani mankhwala oti agwiritse ntchito, mulingo 
wake komanso kutalika kwa kagwiritsidwe ntchito. 
Kuti kafukufukuyu atheke, ndikufunika kupeza uthenga wachitandizo chakuchipatala chomwe 
opanga nawo kafukufukuyu alemberedwa komanso uthenga wamoyo wawo. Uthenga omwe 
uzafunikire ndi tsiku lobadwa, ngati ali wamwamuna kapena wamkazi, kulemera kwathupi, 
mankhwala omwe walemberedwa, kalandiridwe kamankhwala nthupi, katalikidwe kachithandizo 
chakuchipatala komanso matenda ena omwe angakhale apezeka nawo. Choncho ndidzapempha 
mwana wanu kapena amene mumamusunga kuti alowe nawo mukafukufukuyu. Ndizapempha 
chilolezo kuti ndithe kupeza nawo uthenga wachithandizo chomwe mwana wanu kapena omusunga 
walandira kuchipatala komanso uthenga okhudza moyo wake. Zimenezi zidzatenga mphindi 
pafupifupi khumi za nthawi yanu.  
Uthenga omwe udzatengedwe udzasungidwa mwachinsinsi; omwe adzakhale ndimwayi oona 
uthengawo ndi amene akupanga kafukufukuyu ndiomuyang’anira ake. Udzaikidwa muzizindikiro 
ndi ziyankhulo zosiyana ndi momwe udzatengedwere. Udzasindikizidwa mu manambala ndi 
nzithunzi panthawi yotulutsa zosatira zakafukufuku ameneyu. 
Chilolezo chopangira kafukufuku ameneyu chaperekedwa ndi nthambi zoyang’anira kafukufuku za 
Biomedical Research and Ethics Committee ya UKZN ndi College of Medicine Research and 
Ethics Committee (COMREC) ya UNIMA. Kulowa nawo kafukufukuyu ndikosakakamiza ndipo 
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mukhonza kunkaniza mwana wanu kapena omusunga kuti asapange nawo kafukufukuyu kapena 
kumusiyitsira panjira mosachita mantha kapena kulandira chilango. Kuchita nawo kafukufukuyu 
ndikwaulere ndipo palibe cholowa chilichonse chizaperekedwe. 
Ndidzathokoza kwambiri pachilolezo chanu kuti mwana wanu kapena omusunga alowe nawo 
mukafukufukuyu chifukwa kafukufukuyu adzaonjezera uthenga omwe ulipo kale okhudzana ndi 
nthenda yachibayo makamaka kwa ana.  
Ngati muli ndimafunso kapena chidandaulo chokhudzana ndikafukufuku ameneyu, mutha 
kulumikizana ndi amene akupanga kafukufukuyu potchaya lamya pa +265 (0)993 089 868 kapena 
polemba email ku ebmatambo75@gmail.com. Muthanso kunena nkhawa zanu kwa amene 
akumuyang’anira kafukufukuyu polemba email ku vernonsolomon@gmail.com, 
lars.smabrekke@uit.no ndi kkatundu@medcol.mw. Chidandaulo chithanso kuperekedwa kwa 
wapampando wamabungwe amene adapereka chilolezo kuti kafukufuku ameneyu achitike. 
Chidandaulo chitha kuperekedwa kwa wapampando wa BREC ndi COMREC pa ma email adiresi 
ali mmusimu. 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION  
Research Office, Westville Campus  
Govan Mbeki Building  
University of KwaZulu-Natal 
Private Bag X 54001, Durban, 4000  
KwaZulu-Natal, SOUTH AFRICA  
Tel: 27 31 2602486 - Fax: 27 31 2604609  
Email: BREC@ukzn.ac.za   
 
COLLEGE OF MEDICINE RESEARCH AND ETHICS COMMITTEE 
College of Medicine 
Private bag 360 
Chichiri, Blantyre 3 
Email: comrec@medcol.mw 
 
5. Consent form ‘A’ 
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UNIVERSITY OF KWAZULU NATAL 
WESTVILLE CAMPUS 
Consent form 
Aim 
To describe drug choice, dosages and duration of treatment in management of paediatric CAP at 
LHC. 
Researcher: Ernest Matambo     
Supervisor: Lars Smabrekke, Vernon Solomon, Kondwani Katundu   
I ………………………………………………. have discussed the risks and the benefits of the 
study which Ernest Matambo is conducting as a partial fulfillment of his Master’s degree in Health 
sciences. The study is aiming at describing how antibiotics are prescribed in management of 
paediatric community acquired pneumonia at Limbe Health Centre.  
The risk associated with the study is submission of demographic and CAP treatment information for 
my son/daughter/dependant. I know the researcher as Ernest Matambo whom I can contact if I have 
complaints on how the study is being conducted or if confidentiality of my son/daughter/dependant 
is being violated. I am also at liberty to direct my complaints to College of Medicine Research and 
Ethics Committee (COMREC) or University of KwaZulu-Natal Biomedical Research Ethics 
Committee using contact addresses as shown at the end of the consent form. 
I’m informed that I’m participating in this research voluntarily and that I can refuse to participate or 
withdraw from the study at any time without being penalized in any way. 
I’m informed that by signing below I consent that information about my child or dependant should 
be used for the purpose of this research only. 
…………………………………                                             ………………………………. 
Signature                                                                                   Date 
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BIOMEDICAL RESEARCH ETHICS ADMINISTRATION  
Research Office, Westville Campus  
Govan Mbeki Building  
University of KwaZulu-Natal 
Private Bag X 54001, Durban, 4000  
KwaZulu-Natal, SOUTH AFRICA  
Tel: 27 31 2602486 - Fax: 27 31 2604609  
Email: BREC@ukzn.ac.za   
 
COLLEGE OF MEDICINE RESEARCH AND ETHICS COMMITTEE 
College of Medicine 
Private bag 360 
Chichiri, Blantyre 3 
Email: comrec@medcol.mw 
 
6. Consent form ‘B’ 
 
UNIVERSITY OF KWAZULU NATAL 
WESTVILLE CAMPUS 
Kupempha chilolezo kuti mulowe nawo  mukafukufuku 
 Cholinga chakafukufuku  
Kufotokoza kasankhidwe ka mankhwala, mulingo ndi kutalika kwa nthawi yomwera mankhwala 
omwe madotolo amalembera ana odwala chibayo kuchipatala chaching’ono chaku Limbe 
Opanga kafukufuku: Ernest Matambo     
Oyang’anira : Lars Smabrekke, Vernon Solomon, Kondwani Katundu  
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Ine…………………………..ndakambirana ndi Ernest za kafukufuku yemwe akupanga 
pokwanilitsa mbali ina ya maphunziro ake a Masters in Health Sciences. Ernest wandifotokozera 
ubwino ndi chiopsezo chomwe chingakhalepo chokhuzana ndi kafukufuku amene akupangayi 
yemwe cholinga chake ndi kufotokoza kasankhidwe ka mankhwala, mulingo ndi kutalika kwa 
nthawi yomwera mankhwala omwe madotolo amalembera ana odwala chibayo kuchipatala 
chaching’ono chaku Limbe. 
Chiopsezo chomwe chingakhalepo chokhuzana ndi kafukufuku ameneyu ndichakuti 
ndidzapemphedwa kuulula zinthu zina za pamoyo wamwana wanga kapena amene 
ndimamusamalira kuphatikizapo chithandizo chomwe walandila kuchipatala. Ndikumudziwa 
akupanga kafukufukuyu ngat Ernest Matambo. Ngati ndili ndi chidandaulo chokhuzana ndimomwe 
kafukufuku ameneyi akuyendera  kapena ngati ndaona kut ufulu wa mwana wanga kapena 
wayemwe ndimamusalira okhala ndi chinsisi ukuphwanyidwa, ndili ndi ufulu odandaulira Ernest 
Matambo kapenanso kukadandaula ku College of Medicine Research and Ethics Committee 
(COMREC) kapena University of KwaZulu Natal Biomedical Research Ethics Committee 
pogwiritsa ntchito ma adiresi ali kumapeto kwa fomu ino.  
Ndikuthanso kumvetsa kuti ndalowa mukafukufukuyu mosakakamizidwa ndipo ndikhonza kukana 
osapanga nawo kapena kumusiila panjira opanda kulandila chilango chilichonse 
Ndikudziwanso kuti poika chisindikizo changa  pansipa ndikuvomereza kuti umboni wa moyo wa 
mwana wanga kapena mwana amene ndimamusamalira  ugwiritsidwe ntchito pakafukufuku 
yekhayu basi. 
 
……………………………………….                                      ………………………………... 
Chisindikizo                                                                                Tsiku 
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION  
Research Office, Westville Campus  
Govan Mbeki Building  
University of KwaZulu-Natal 
Private Bag X 54001, Durban, 4000  
KwaZulu-Natal, SOUTH AFRICA  
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Tel: 27 31 2602486 - Fax: 27 31 2604609  
Email: BREC@ukzn.ac.za   
 
COLLEGE OF MEDICINE RESEARCH AND ETHICS COMMITTEE 
College of Medicine 
Private bag 360 
Chichiri, Blantyre 3 
Email: comrec@medcol.mw 
 
7. Consent form to prescribers  
 
UNIVERSITY OF KWAZULU NATAL 
WESTVILLE CAMPUS 
Consent form 
Aim 
To describe antibiotic drug treatment in the management of non-severe paediatric Community 
Acquired Pneumonia  at Limbe Health Centre, Blantyre. 
Researcher: Ernest Matambo     
Supervisor: Lars Smabrekke, Vernon Solomon, Kondwani Katundu   
I ………………………………………………. have discussed the risks and the benefits of the 
study which Ernest Matambo is conducting as a partial fulfillment of his Master’s degree in Health 
sciences. The study is aiming at describing how antibiotics are prescribed in treatment of paediatric 
Community Acquired Pneumonia at Limbe Health Centre.  
The risk associated with the study is submission of my demographic and academic qualification 
information. I know the researcher as Ernest Matambo whom I can contact if I have complaints on 
how the study is being conducted or if my confidentiality is being violated. I am also at liberty to 
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direct my complaints to College of Medicine Research and Ethics Committee (COMREC) or 
University of KwaZulu-Natal Biomedical Research Ethics Committee using contact addresses as 
shown at the end of the consent form. 
I’m informed that I’m participating in this research voluntarily and that I can refuse to participate or 
withdraw from the study at any time without being penalized in any way. 
I’m informed that by signing below I consent that the information I will be provide should be used 
for the purpose of this research only. 
…………………………………                                             ………………………………. 
Signature                                                                                   Date 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION  
Research Office, Westville Campus  
Govan Mbeki Building  
University of KwaZulu-Natal 
Private Bag X 54001, Durban, 4000  
KwaZulu-Natal, SOUTH AFRICA  
Tel: 27 31 2602486 - Fax: 27 31 2604609  
Email: BREC@ukzn.ac.za   
 
COLLEGE OF MEDICINE RESEARCH AND ETHICS COMMITTEE 
College of Medicine 
Private bag 360 
Chichiri, Blantyre 3 
Email: comrec@medcol.mw 
 
8. Coding of variables  
Case number: Consecutive numbers starting from 1 
Patient’s age: Age in months  
Patient’s weight: Weight in kg  
Patient’s gender: Male =1 and female = 2 
Prescribed drug: amoxicillin = 1, cotrimoxazole = 2, erythromycin = 3 
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Daily dose: prescribed daily dose in mg  
Duration of treatment: Number of days  
Other comorbidities: HIV/AIDS =1, TB = 2, Asthma = 3, other comorbidities = 4, not present = 5 
Prescriber’s qualification: Certificate in clinical medicine = 1, diploma in clinical medicine = 2  
Prescriber’s gender: Male = 1, female = 2 
Prescriber’s years of practice = Number of years of practice  
